Medicine

Using a large language model AI, biotech startup Profluent has created new antimicrobial proteins.

Delivering chemotherapy to colon cancer patients before and after surgery — instead of just after — reduces their risk of recurrence by 28%.

Using spiraling ultrasound waves, researchers hope to remove stroke-causing blood clots faster and safer.

A microbiome-friendly method of controlling Staph colonization has aced phase 2 clinical trials.

Alto Neuroscience’s depression drug seems effective in early trials, a proof-of-concept for biomarker-based design.

BioNTech is sending a modular mRNA vaccine factory that can produce 50 million COVID-19 vaccines annually to Africa.

Moderna’s mRNA RSV vaccine for adults looks to be over 80% effective, based on early data from a large phase 3 trial.

A new delivery method for mRNA therapies could open the doors to better treatments for aging, cancer, and more.

A “morning after” antiviral nasal spray could be created using new knowledge about how SARS-CoV-2 invades your nose.

After a monumental year of breakthroughs, scientists, investors, and CEOs share which areas of biotech they are eagerly watching this year.